97 related articles for article (PubMed ID: 28104253)
1. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Morrow SA; Rosehart H; Johnson AM
Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
[TBL] [Abstract][Full Text] [Related]
2. Aminopyridines for symptomatic treatment in multiple sclerosis.
Solari A; Uitdehaag B; Giuliani G; Pucci E; Taus C
Cochrane Database Syst Rev; 2001; 2002(4):CD001330. PubMed ID: 11687106
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
4. Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail.
Mavandadi S; Paybast S; Mirzadeh M; Mozhdehipanah H
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38582798
[TBL] [Abstract][Full Text] [Related]
5. Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study.
Thorning M; Lambertsen KL; Jensen HB; Frich LH; Madsen JS; Olsen DA; Holsgaard-Larsen A; Nielsen HH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338871
[TBL] [Abstract][Full Text] [Related]
6. Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis.
Rouhani M; Tolentino M; Lyons JA; Ng AV
Mult Scler Relat Disord; 2024 Jun; 86():105598. PubMed ID: 38614054
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial.
Prosperini L; Castelli L; De Giglio L; Bonanno V; Gasperini C; Pozzilli C
Neurotherapeutics; 2020 Apr; 17(2):704-709. PubMed ID: 31820274
[TBL] [Abstract][Full Text] [Related]
8. Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE).
Hof S; van Rijn LJ; Uitdehaag BMJ; Nij Bijvank JA; Petzold A
BMJ Open; 2024 Jan; 14(1):e076651. PubMed ID: 38296293
[TBL] [Abstract][Full Text] [Related]
9. Cognition and Cognitive Fatigability: Association with Employment Status in Multiple Sclerosis.
MacAdam ES; Berard JA; Walker LAS
Can J Neurol Sci; 2023 Nov; 50(6):870-875. PubMed ID: 36280897
[TBL] [Abstract][Full Text] [Related]
10. Does multilingualism act as a protective factor (cognitive reserve) against cognitive impairment in multiple sclerosis?: A retrospective cohort study.
Morrow SA; Balusha AAK; Rosehart H; Casserly C; Racosta JM
Mult Scler Relat Disord; 2023 Dec; 80():105060. PubMed ID: 37866025
[TBL] [Abstract][Full Text] [Related]
11. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).
Goodman AD; Stone RT
Neurotherapeutics; 2013 Jan; 10(1):106-10. PubMed ID: 23184313
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
Leavitt VM; Tozlu C; Nelson KE; Boehme AK; Donnelly JE; Aguerre I; Spinner M; Riley CS; Stein J; Onomichi K
J Neurol; 2024 May; 271(5):2207-2215. PubMed ID: 38413464
[TBL] [Abstract][Full Text] [Related]
13. Validation of Discrete and Regression-Based Performance and Cognitive Fatigability Normative Data for the Paced Auditory Serial Addition Test in Multiple Sclerosis.
Walker CS; Berard JA; Walker LAS
Front Neurosci; 2021; 15():730817. PubMed ID: 34867152
[TBL] [Abstract][Full Text] [Related]
14. A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
Chase E; Chen V; Martin K; Lane M; Wooliscroft L; Adams C; Rice J; Silbermann E; Hollen C; Fryman A; Purnell JQ; Vong C; Orban A; Horgan A; Khan A; Srikanth P; Yadav V
Mult Scler; 2023 Nov; 29(13):1659-1675. PubMed ID: 37941305
[TBL] [Abstract][Full Text] [Related]
15. Fatigue may improve equally after balance and endurance training in multiple sclerosis: a randomised, crossover clinical trial.
Perucca L; Scarano S; Russo G; Robecchi Majnardi A; Caronni A
Front Neurol; 2024; 15():1274809. PubMed ID: 38385033
[TBL] [Abstract][Full Text] [Related]
16. Effect of methylphenidate on oculomotor function in individuals with multiple sclerosis: a pilot randomized placebo-controlled trial.
Rich TJ; Alexander A; Dobryakova E; Chiaravalloti ND; DeLuca J; Costa SL
Front Neurol; 2024; 15():1393877. PubMed ID: 38846035
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the effects of brain injury, disease and tasks on cognitive fatigue.
Wylie GR; Genova HM; Yao B; Chiaravalloti N; Román CAF; Sandroff BM; DeLuca J
Sci Rep; 2023 Nov; 13(1):20166. PubMed ID: 37978235
[TBL] [Abstract][Full Text] [Related]
18. Does intensity matter? A randomized crossover study of the role of acute exercise intensity on cognitive performance and motor speed and accuracy.
Larson MJ; Muir AM; Reid RO; Carbine KA; Marsh H; LaCouture H; McCutcheon C; Bailey BW
Prog Brain Res; 2024; 283():99-121. PubMed ID: 38538194
[TBL] [Abstract][Full Text] [Related]
19. Two-month period of 500 mg lecithin-based delivery form of quercetin daily dietary supplementation counterbalances chronic fatigue symptoms: A double-blind placebo controlled clinical trial.
Rondanelli M; Riva A; Petrangolini G; Gasparri C; Perna S
Biomed Pharmacother; 2023 Nov; 167():115453. PubMed ID: 37716119
[TBL] [Abstract][Full Text] [Related]
20. The spectral slope as a marker of excitation/inhibition ratio and cognitive functioning in multiple sclerosis.
Akbarian F; Rossi C; Costers L; D'hooghe MB; D'haeseleer M; Nagels G; Van Schependom J
Hum Brain Mapp; 2023 Dec; 44(17):5784-5794. PubMed ID: 37672569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
